产品说明书

HCH6-1

Print
Chemical Structure| 1435265-06-7 同义名 : -
CAS号 : 1435265-06-7
货号 : A1176435
分子式 : C28H27N3O4
纯度 : 99%+
分子量 : 469.532
MDL号 : MFCD32197174
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 250 mg/mL(532.45 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • FPR1
描述 During the inflammatory process, neutrophils are recruited into inflammatory areas to eliminate invasive pathogens. Formyl peptide receptor 1 (FPR1) typically facilitates neutrophil immune responses in the presence of N-formyl peptides derived from bacteria in vitro. HCH6-1, a competitive dipeptide antagonist of FPR1, shows a potent inhibitory effect on FPR1-agonist-activated human neutrophils. HCH6-1 significantly inhibited superoxide anion generation in fMLF (FPR1 agonist)-activated neutrophils, with IC50 of 0.32 ± 0.03 μM. Further, HCH6-1 significantly inhibited elastase release in fMLF-activated neutrophils, with IC50 of 0.57 ± 0.07 μM. HCH6-1 dose dependently diminished CD11b expression up-regulated by fMLF in human neutrophils. Furthermore, HCH6-1 reduced the neutrophil migration induced by fMLF suggesting that HCH6-1 impaired chemotaxis only in FPR1-activated neutrophils. Compared with the controls, in treated neutrophils, HCH6-1 dose-dependently inhibited the binding of FNLFNYK to FPR1. The protective effect of HCH6-1 in LPS (lipopolysaccharide)-induced ALI (acute lung injury) was tested in vivo. HCH6-1 pretreatment reduced inflammatory cell infiltration and distortion of pulmonary architecture in the presence of LPS[1].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.65mL

2.13mL

1.06mL

21.30mL

4.26mL

2.13mL
参考文献

[1]Yang SC, Chang SH, Hsieh PW, et al. Dipeptide HCH6-1 inhibits neutrophil activation and protects against acute lung injury by blocking FPR1. Free Radic Biol Med. 2017;106:254-269